Endocrinology · Obesity and Type 2 DiabetesTrial Updateclinicalmid-term

Amgen's MARITIME-2-EXTENSION Trial Evaluates Maridebart Cafraglutide for Obesity and Type 2 Diabetes

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Amgen12 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/20/2026, 12:30:36 PM

Assessment confidence: 68% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The MARITIME-2-EXTENSION trial is crucial for understanding the long-term efficacy and safety of maridebart cafraglutide, which could significantly impact Amgen's competitive positioning in the obesity and diabetes markets. Positive trial outcomes may enhance Amgen's portfolio and market share in these therapeutic areas. Regulatory context from FDA (FDA AP — REPATHA (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).

Strategic Assessment

Positive outcomes may enhance Amgen's portfolio in the obesity and diabetes space, potentially leading to increased market share. The strongest clinical anchor is A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) (ClinicalTrials.gov), sponsor/company relevance (merck). In Endocrinology · Obesity and Type 2 Diabetes, 6 regulatory and 1 competitive items passed relevance filtering for Amgen.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). This trial could provide critical data on the long-term use of maridebart cafraglutide, influencing its competitive positioning against other obesity and diabetes therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — REPATHA (SUPPL) (FDA). Entity match (amgen); Regulatory pathway relevance (bla). The trial's findings will likely influence future regulatory submissions and labeling for maridebart cafraglutide, impacting its market entry and competitive landscape.

Key Risks

Elevated medium regulatory exposure for Amgen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful trial results could lead to increased adoption of maridebart cafraglutide, potentially boosting Amgen's revenue and market share in the obesity and diabetes segments.
Positive outcomes may enhance Amgen's portfolio in the obesity and diabetes space, potentially leading to increased market share.

What Would Change This Assessment

This becomes more urgent if Monitor results from the trial and any subsequent regulatory filings or market strategies based on the findings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — REPATHA (SUPPL)
FDAhigh relevance
Entity match (amgen); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — BKEMV (SUPPL)
FDAhigh relevance
Entity match (amgen); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — PROLIA (SUPPL)
FDAhigh relevance
Entity match (amgen); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — PAVBLU (SUPPL)
FDAhigh relevance
Entity match (amgen); Regulatory pathway relevance (bla)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves Drug for Pediatric Stage 3 Type I Diabetes
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial of Treatments for COVID-19 in Hospitalized Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Amgen
obesity therapies
diabetes therapies

Commercial impact

medium

Successful trial results could lead to increased adoption of maridebart cafraglutide, potentially boosting Amgen's revenue and market share in the obesity and diabetes segments.

Regulatory impact

medium

The trial's findings will likely influence future regulatory submissions and labeling for maridebart cafraglutide, impacting its market entry and competitive landscape.

What to watch

Monitor results from the trial and any subsequent regulatory filings or market strategies based on the findings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.